Atrium Therapeutics, Inc.
$14.3
▼
-0.22%
2026-04-21 09:11:00
atriumtherapeutics.com
NMS: RNA
Explore Atrium Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$239.4 M
Current Price
$14.3
52W High / Low
$73.06 / $11.95
Stock P/E
—
Book Value
$-4.04
Dividend Yield
—
ROCE
-32.47%
ROE
-104.92%
Face Value
—
EPS
$-4.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
0.02
Current Ratio
0.07
Quick Ratio
6.53
Forward P/E
-3.15
Price / Sales
10.59
Enterprise Value
—
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 2. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 3. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 4. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 5. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 6. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 7. | Azitra, Inc. | $0.21 | — | $3.48 M | — | -277.12% | -2.31% | $2.66 / $0.1 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q4 2024 | |
|---|---|---|
| Sales | 0.86 M | 2.97 M |
| Operating Profit | -48.03 M | -44.25 M |
| Net Profit | -48.07 M | -46.2 M |
| EPS in Rs | -3.1 | -2.98 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 18.62 M | 10.9 M | 9.76 M |
| Operating Profit | -76.81 M | -13.22 M | -6.39 M |
| Net Profit | -76.68 M | -25.12 M | -6.38 M |
| EPS in Rs | -4.94 | -1.62 | -0.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 278.35 M | 7.19 M | 10.29 M |
| Total Liabilities | 71.07 M | 68.29 M | 80.91 M |
| Equity | 207.29 M | -61.11 M | -70.62 M |
| Current Assets | 272.85 M | 0.48 M | 0.86 M |
| Current Liabilities | 41.8 M | 26.8 M | 33.8 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -41.13 M | -22.55 M | 56.39 M |
| Investing CF | -1.45 M | -0.27 M | -0.32 M |
| Financing CF | 42.57 M | 22.82 M | -56.07 M |
| Free CF | -42.57 M | -22.82 M | 56.07 M |
| Capex | -1.45 M | -0.27 M | -0.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | 70.85% | 11.6% | — |
| Earnings Growth % | -205.25% | -293.45% | — |
| Profit Margin % | -411.88% | -230.54% | -65.39% |
| Operating Margin % | -412.58% | -121.3% | -65.4% |
| Gross Margin % | — | — | — |
| EBITDA Margin % | -410.84% | -119.72% | -63.99% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.